drugset / Trial / NCT01326858

Safety and Comfort of AL-4943A Ophthalmic Solution

NCT01326858

Phase 1 Completed 50 enrolled Alcon Research
RandomizedCrossoverDouble-blind

Summary

The purpose of this study is to assess the ocular comfort and safety of olopatadine hydrochloride opthalmic solution. 0.7%.

Timeline

Start
2011-04
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketotifen Small molecule 0.025 % Other
Subject Olopatadine Other / unclassified 0.7 % Other

Indications